Latest News

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
04/04/14AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
REDWOOD CITY, Calif., April 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, and Timothy E. Morris, CFO, will present a Company update on April 9th. Presentation details are as follows: 13th Annual Needham Healthcare Conference   Date:  Wednesday, April 9, 2014  ... 
Printer Friendly Version
03/25/14AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer
REDWOOD CITY, Calif., March 25, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Timothy E. Morris as chief financial officer (CFO).  Mr. Morris brings 30 years of professional finance and accounting experience to AcelRx, 18 of those years spent in the role of chief financial officer, most... 
Printer Friendly Version
03/07/14AcelRx Pharmaceuticals to Participate at the 26th Annual Roth Conference
REDWOOD CITY, Calif., March 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update at the following conference: 26th Annual Roth Conference Date:  Tuesday, March 11, 2014 Location:  The Ritz Carlton, Laguna Niguel, CA Presentation Time:  1... 
Printer Friendly Version
03/03/14AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
REDWOOD CITY, Calif., March 3, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013. "AcelRx made strong progress in 2013 with the successful completion of the Zalviso™ (sufentanil sublingual NanoTab system) Phase 3 program, the filing a... 
Printer Friendly Version
02/24/14AcelRx Pharmaceuticals to Hold Fourth Quarter and Annual 2013 Financial Results Conference Call and Webcast on Monday, March 3, 2014
REDWOOD CITY, Calif., Feb. 24, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter 2013 financial results after market close on Monday, March 3, 2014.  AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Ma... 
Printer Friendly Version
02/05/14AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
REDWOOD CITY, Calif., Feb. 5, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will be presenting a Company update at three upcoming investor conferences.  Details of the three events are as follows: BIO CEO & Investor Conference Date:  Tuesday, February 11, 2014 ... 
Printer Friendly Version

AcelRX

CONTACT